- |||||||||| NLRP3 inhibitor / Halia Therap, HT-6184 / Halia Therap
HT-6184 Inhibits the Formation of the NLRP3 Inflammasome in Human Monocytic THP-1 Cells (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5330;
Since THP-1 cells are a monocytic cell line, this data suggests our ability to inhibit the NLRP3 pathway in hematological disorders effectively. By preventing inflammasome formation and activation, we expect to be able to reduce disease burden in hematological diseases.
- |||||||||| HT-6184 / Halia Therap
The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML (Halls G-H (San Diego Convention Center)) - Nov 3, 2023 - Abstract #ASH2023ASH_1824;
Background: The NLRP3 inflammasome is one of the key biological drivers of ineffective hematopoiesis and inflammation in myelodysplastic syndrome (MDS). These findings demonstrate that the novel dual inflammasome/myddosome inhibitor, HT-6184 effectively suppresses myeloid skewing, restores erythroid commitment in MDS/AML specimens, and provides a rationale for clinical development in myeloid malignancies.
- |||||||||| NLRP3 inhibitor / Halia Therap, HT-6184 / Halia Therap
Modulation of NLRP3 Inflammasome in Monocytes By HT-6184 in a Single-Cell Proteomic Study (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_1562;
Further research should explore the characteristics of HT-6184 and its ability to modulate the inflammasome in diverse in vitro and in vivo models. The modulation of the NLRP3 inflammasome by HT-6184 holds potential therapeutic implications for managing inflammatory disorders associated with dysregulated NLRP3 activation.
- |||||||||| HT-6184 / Halia Therap
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate HT-6184 in Healthy Subjects (clinicaltrials.gov) - Aug 28, 2023
P1, N=64, Completed,
The modulation of the NLRP3 inflammasome by HT-6184 holds potential therapeutic implications for managing inflammatory disorders associated with dysregulated NLRP3 activation. Recruiting --> Completed | N=32 --> 64 | Trial completion date: Nov 2022 --> Jul 2023 | Trial primary completion date: Oct 2022 --> Jul 2023
|
